JP2015517458A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517458A5
JP2015517458A5 JP2015509430A JP2015509430A JP2015517458A5 JP 2015517458 A5 JP2015517458 A5 JP 2015517458A5 JP 2015509430 A JP2015509430 A JP 2015509430A JP 2015509430 A JP2015509430 A JP 2015509430A JP 2015517458 A5 JP2015517458 A5 JP 2015517458A5
Authority
JP
Japan
Prior art keywords
insulin
combination
des
human insulin
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015509430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517458A (ja
JP6262206B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/059073 external-priority patent/WO2013164375A1/en
Publication of JP2015517458A publication Critical patent/JP2015517458A/ja
Publication of JP2015517458A5 publication Critical patent/JP2015517458A5/ja
Application granted granted Critical
Publication of JP6262206B2 publication Critical patent/JP6262206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015509430A 2012-05-01 2013-05-01 医薬組成物 Active JP6262206B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12166251.4 2012-05-01
EP12166252 2012-05-01
EP12166251 2012-05-01
EP12166252.2 2012-05-01
US201261641540P 2012-05-02 2012-05-02
US201261641544P 2012-05-02 2012-05-02
US61/641,544 2012-05-02
US61/641,540 2012-05-02
PCT/EP2013/059073 WO2013164375A1 (en) 2012-05-01 2013-05-01 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2015517458A JP2015517458A (ja) 2015-06-22
JP2015517458A5 true JP2015517458A5 (enExample) 2016-06-16
JP6262206B2 JP6262206B2 (ja) 2018-01-17

Family

ID=49514218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015509430A Active JP6262206B2 (ja) 2012-05-01 2013-05-01 医薬組成物

Country Status (9)

Country Link
US (1) US9884094B2 (enExample)
EP (1) EP2844274B1 (enExample)
JP (1) JP6262206B2 (enExample)
AU (1) AU2013255880B2 (enExample)
BR (1) BR112014026442A8 (enExample)
CA (1) CA2872083A1 (enExample)
MX (1) MX363119B (enExample)
RU (1) RU2670106C2 (enExample)
WO (1) WO2013164375A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US20160296602A1 (en) * 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
EP2991672A1 (en) * 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
WO2016001185A1 (en) * 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
ATE300519T1 (de) 1989-04-19 2005-08-15 Enzon Inc Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
ES2472421T3 (es) 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー/エス インスリン誘導体を含有する薬学的製剤
JP5781308B2 (ja) * 2008-02-19 2015-09-16 バイオコン・リミテッドBiocon Limited 異種タンパク質を得る方法およびインスリン類似体
CN102202683A (zh) * 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
KR20130139297A (ko) * 2010-10-27 2013-12-20 노보 노르디스크 에이/에스 다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료

Similar Documents

Publication Publication Date Title
JP5669395B2 (ja) 新規化合物および摂食行動に対するその効果
RU2014147674A (ru) Фармацевтическая композиция
JP2016516076A5 (enExample)
RU2011117645A (ru) Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
JP2009533460A (ja) hGLP−1、エクセンジン−4およびその類似体の医薬組成物
JP2017537894A (ja) Glp−1rおよびglp−2r二重アゴニスト活性を有する組成物及びペプチド
RU2013133803A (ru) Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп
CA2608311A1 (en) Glp-1 pegylated compounds
JP2010031018A5 (enExample)
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
RU2006144821A (ru) Пролонгирующие метки полипептидов, содержащие тетразольную группировку
JP2015110631A5 (enExample)
CN102711805A (zh) 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
JP2011503152A5 (enExample)
US20150111820A1 (en) Novel use of insulin derivatives
EP1888103B1 (en) Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
JP2024038042A (ja) 肥満の治療および体重管理のためのglp-1組成物
JP2014500244A5 (enExample)
Verge et al. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes
JP2013511287A5 (enExample)
Mikhail Is exenatide a useful addition to diabetes therapy?
Skurikhin et al. Effects of Pegylated Glucagon-Like Peptide-1 Analogue in C57Bl/6 Mice under Optimal Conditions and During Streptozotocin-Induced Diabetes
Kanaujia et al. BEYOND BORDERS: TIRZEPATIDE UNVEILED-A COMPREHENSIVE REVIEW OF DUAL TARGETING THERAPIES IN DIABETES AND OBESITY MANAGEMENT.
KR20260022330A (ko) 대사 장애의 치료에 사용하기 위한 glp-1 유사체
NZ753010A (en) Acylated glp-1/glp-2 dual agonists